Last year when Hikma bought Boehringer Ingelheim's Ben Venue injectable business, it decided not to reopen its long-troubled Bedford, OH, plant. But with a $2.65 billion deal announced today for Boehringer's Roxane generics business, it gets a U.S. manufacturing plant that it says it likes the looks of.
Novartis's generics business Sandoz provided the key bright spot in an otherwise tough earnings report for the Swiss pharma, with revenues up 10%. But the starring performance did not keep the manufacturing side of Sandoz from getting spanked, with three of its plants now targeted for closing.
When Biogen announced a few weeks ago that it intends to build a $1 billion new biologics plant in Switzerland, officials said the Cambridge, MA-based company had more manufacturing expansion up its sleeve. At least part of the great reveal was made last week when Japanese partner Eisai said it was turning over manufacturing operations in North Carolina to Biogen.
POPULAR COMMENT THREADS
After recalling 18 million vials last January of a painkiller commonly used in surgery, sterile injectables maker Hospira indicated that it was on top of the problem. But the company now says new manufacturing issues have cropped up that have led it to recall more than 20.7 million more vials of ketorolac, a drug on the FDA shortage list.
Upsher-Smith had to quit shipping fluoxymesterone tablets last fall when its supplier quit making the API for Androxy. The problem was that Upsher-Smith is the only supplier in the U.S. for the drug, which is used to treat breast cancer in women and low testosterone in men. Now Upsher-Smith says Androxy is back.
Teva Pharmaceutical Industries voluntarily recalled 8 lots of a cancer drug a couple of months ago after rubber particles were found in some containers. Now the generics maker says the problem is more widespread than it first thought and more units will need to be retrieved.
Avista Pharma Solutions has snapped up the manufacturing, development and animal health services business from rival Scynexis in a move designed to bulk up its capacity and garner a larger share of the growing market.
The European Union will impose a ban starting Aug. 21 on more than 700 drugs that were bioequivalency tested by India's GVK BioSciences after inspectors raised questions about its procedures.
India's Lupin has landed its first manufacturing site in the U.S. with an $880 million deal to buy a small generics maker in New Jersey that specializes in niche products including dermatology controlled substances.
From Our Sister Sites
Israeli Parkinson's specialist Intec Pharma and drug delivery device maker EyeGate aim to debut on the Nasdaq this week for a combined $51 million.
RNAi specialist Alnylam initiated Phase I/II trials of its candidate to treat AAT deficiency-associated liver disease (alpha-1 liver disease).